GlassScriptPhysician profile
Karina Marquez
NPI 1013588565
$1,508.01
in general payments reported to CMS, 2019-2025
21 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.67 · 2022: $130 · 2023: $318 · 2024: $370 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.74 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $158.33 | 2023-2025 | Rybelsus, Ozempic |
| Amgen INC. | $148.23 | 2023-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $133.75 | 2024-2025 | |
| Pfizer INC. | $99.29 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.67 | 2022-2025 | |
| Exact Sciences Corporation | $79.37 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $69.14 | 2022-2023 | |
| Cranial Technologies, INC | $66.86 | 2022-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $59.53 | 2023-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $54.14 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $49.14 | 2022-2025 | Enflonsia, Rotateq, Gardasil 9 |
| Rgh Enterprises LLC | $41.24 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.06 | 2021-2025 | Xifaxan, Trulance |
| Acadia Pharmaceuticals INC | $36.50 | 2025 | Daybue |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.86 | 2021-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $25.06 | 2025 | Korlym |
| Amarin Pharma, INC. | $21.41 | 2022 | |
| Madrigal Pharmaceuticals | $18.94 | 2025 | Rezdiffra |
| Phadia US INC. | $17.27 | 2023 | Immunocap |
| Paratek Pharmaceuticals, INC. | $15.48 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.